EUVIMED · CrossrefJournal
Journal of Hepatology
ISSN 0168-8278 · Elsevier BV
Latest articles
From the Editor’s Desk...
Editorial Board
Get ready for EASL Congress 2027 and submit your abstract by 19 January!
Register for the EASL Liver Cancer Summit 2027! 14-16 January, Valencia (Spain)
Register for the EASL Steatotic Liver Disease Summit 2027! 10-13 February, Berlin (Germany)
MICROB-PREDICT works on identifying microbiome-based predictors and mechanisms of decompensated liver cirrhosis & ACLF, and develop personalised treatment strategies. Discover the project!
Contents
JHEP at a glance (December 2026)
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma
Regression of liver cirrhosis
MRI-based prediction of very early recurrence within 1 year after resection of HCC: An international cohort study
Reply to: “Agree to disagree; increasing the impact of recommendations formulated through Delphi methodology”
HbA1c trajectories and the risk of liver-related events in patients with type 2 diabetes mellitus
Fibrosis regression in chronic liver disease: The pathologist’s view
Baveno VIII – Advancing consensus in portal hypertension
Liver biopsy confirms precise and efficient correction of SERPINA1 after in vivo Base Editing in a Patient with Alpha-1 Antitrypsin Deficiency
Seladelpar for alkaline phosphatase normalization in primary biliary cholangitis: The IDEAL phase III randomized controlled trial
Programming the gut-liver-brain axis: a new frontier for hepatic encephalopathy?
Hidden in plain sight: Quiescent tumour cells and immune remodelling shape HCC metastatic colonization
Semaglutide targets two major drivers of liver disease
Senescence induces clonal failure of hepatocyte plasticity and reshapes regenerative lineages
Translocation of the environmental bacterium Aquitalea magnusonii promotes systemic inflammation and liver fibrosis in chronic liver disease
T cells and the bile duct: CD226-NECTIN2 as a druggable axis in immune-mediated cholangiopathy
Checkpoint Inhibition during primary hepatitis E virus infection alters memory development of virus-specific T-cells in humans
From the Editor’s Desk...
Advances in the imaging of liver cancer
Surveillance of patients at risk of liver cancer: Expert opinions
Artificial intelligence and personalised medicine in liver cancer
Acute-on-chronic liver failure: A global multisociety consensus on definitions
Reply to: "beyond portal pressure: what does CIRI really predict?" and "can the CIRI model reliably predict cACLD decompensation for clinical adoption?"
Volumes
2026 · 2,8462025 · 2,5162024 · 2,4002023 · 2,4642022 · 2,2702021 · 5912020 · 2,2122019 · 2,1942018 · 2,2872017 · 2,2362016 · 2,1572015 · 2,1352014 · 2,0862013 · 1,9982012 · 2,0282011 · 1,9082010 · 1,6162009 · 1,5022008 · 1,4132007 · 1,1792006 · 1,1792005 · 1,1732004 · 1,1112003 · 1,1762002 · 1,3272001 · 2,0652000 · 1,1741999 · 4141998 · 1,0861997 · 4391996 · 2951995 · 3151994 · 1,0161993 · 3341992 · 2691991 · 9371990 · 6951989 · 6491988 · 5211987 · 584
EUVIMED